Abstract 1797P
Background
In recent years, people have made a lot of efforts in improving the chemotherapy regimens of extensive-stage small cell lung cancer, among which the most authoritative clinical studies are IMPOWER133 and CASPIAN. However, the relevant results show that the combination of PD-L1 monoclonal antibody first-line and EC regimen chemotherapy, the median PFS is about 5 months, which is not obvious longer than simple chemotherapy. Therefore, the EP / EC scheme is still the standard chemotherapy for extensive small cell lung cancer. At the same time, we noticed that in the ALER1202 study in China, Anlotinib Hydrochloride (multi-target small molecule oral VEGF inhibitor) has a curative effect on patients with extensive third-line SCLC in third-line and above. Therefore, we tried to use Anlotinib Hydrochloride combined with EP / EC regimen in first-line SCLC patients to observe the efficacy and adverse reactions.
Methods
SCLC pts (18-75 years old, initial treatment, no obvious heart, liver and kidney dysfunction) received Anlotinib Hydrochloride (12mg QD from day 1 to 14 of a 21-day cycle) +etoposide(100mg/m2 , d1∼3 of 21-day cycle)+CBP (AUC=4-5 ,Q3W)/DDP (70mg/m2, d1,Q3W) for 4∼6 cycles, then Anlotinib Hydrochloride maintenance (12mg QD from day 1 to 14). Until the disease progresses or an intolerable adverse reaction occurs. The main observation endpoints were ORR, PFS and adverse reactions.
Results
From January 2019 to April 2020, our center enrolled 15 patients with extensive SCLC, with an average age of 65.53 ± 7.76 (45-75), 13 males (86.67%) and 2 females (13.33%). The median PFS was 9.0 (95% CI: 4.1-13.9); ORR was 80% and DCR was 100%. The adverse reactions above grade 3 were: white blood cell decline was 5/15 (33.3%), nausea and fatigue, hypertension, and thrombocytopenia were 2/15 (13.3%), hoarseness and anemia were 1/15 (6.7%).
Conclusions
Anlotinib Hydrochloride combined with EP / EC scheme has well PFS, ORR, DCR for the initial treatment of extensive SCLC, and the side effects can be controlled. A randomized, controlled phase III clinical study will be conducted to confirm this.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tiandong Kong.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.